Caplin Point Laboratories Ltd

FDA inspection update

• US FDA conducted unannounced inspection Aug 13–21, 2026 at Caplin Steriles' Gummidipoondi facility.
• Form 483 issued with 10 procedural observations, none related to data integrity, no repeats.
• Company to address observations and respond within the regulatory timeframe.
• Implication: no immediate action disclosed; no data indicating enforcement action.

Filing Status

• This chunk contains only wrapper metadata; no substantive transcript content.

Meeting details

• Q1 FY27 earnings call held Aug 12, 2026 (virtual) with analysts and investors; transcript available on company website.

Meeting Details

• Date and time: August 12, 2026, 16:30 IST.
• Type and mode: Earnings Call; audio recording.
• Event: Analyst/Investor Meet – Earnings Call for Q1 FY 2026-27.
• Key participant: General Counsel & Company Secretary.
• Purpose: Earnings discussion for Q1 FY 2026-27 with analysts.
• Availability: Audio recording posted on the company website.

MD Re-appointment

• Re-appointment of Dr. Sridhar Ganesan, MD, 35+ years pharma leadership, for two years (Aug 25, 2026–Aug 24, 2028).

WTD appointment and CFO

• Appointment of D. Muralidharan as WTD; CFO since 2016, for two years (Aug 12, 2026–Aug 11, 2028).

Consolidated results (Q1 FY27)

• Total revenue ₹643.91 Cr; YoY +20.7%; QoQ +2.4%.
• Revenue from operations ₹610.36 Cr; YoY +19.6%.
• Gross profit ₹365.16 Cr; gross margin 59.8%.
• EBITDA ₹247.03 Cr; EBITDA margin 38.4%.
• PBT ₹225.22 Cr; tax ₹46.13 Cr; PAT ₹179.09 Cr.
• EPS: Basic ₹23.27; Diluted ₹23.21.
• Operating cash flow ₹95 Cr; free cash flow ₹40 Cr after ₹55 Cr capex.
• Inventories ₹505 Cr; receivables 128 days.
• Free cash reserves ₹1,502 Cr; total liquid assets ₹2,875 Cr.
• Geography mix: Emerging markets 78%, US 22%.
• 12M FY26 revenue ₹2,302.73 Cr; YoY +13.2%.

Capex & capacity expansion

• Capex budget around ₹1,000+ Cr; ~50% near completion; funded from internal accruals.
• Capex projects include CP1 Puducherry and Visakhapatnam API upgrade.
• Oncology facilities at Kakkalur and Thervoy; OSD and Dermatology in Pondicherry.
• COL-II facility to house 5 lines; completion by Mar-27; 3 lines optional.
• Amaris Clinical expansion to 120 beds; completion targeted FY27.
• Internal accrual financing; company to remain net cash positive.

US & Regulated markets

• CSL: 60 ANDAs approved; 5 under review; 50 internally developed; 15 acquired.
• 110+ non-US filings; 65 approved; 60+ filings planned in 18 months.
• 38 US launches to date; 12 more planned in FY27.
• COL-II facility to complete by Mar-27; 5 injectable, ophthalmic, BFS lines; 3 more lines.
• CSU: 33 US product launches; 10 more planned in FY27.
• US market share: launched products achieving ~90% share growth.
• Automation: logbooks to digital; electronic batch records planned; QC/micro automation complete.

Emerging Markets highlights

• LatAm growth across geographies; emergency tenders in Central America worth $7m.
• Chile: private and tender market growth; tenders worth $12m over 18 months.
• Mexico: 4 product approvals; 120+ product pipeline in development.
• Oncology API unit Thervoy to be completed by FY27; DMFs planned thereafter.
• Pondicherry project to double capacity; meeting growing demand in regulated markets.
• Amaris Clinical expansion to 120 beds; project to complete by FY27.

Dividends

• Interim dividend Rs 4 per equity share paid on 8 Jun 2026.
• Final dividend proposed Rs 4 per equity share for FY26, subject to AGM.
• Total dividend for FY26 expected to be Rs 8 per share.

Business overview

• Business focuses on pharmaceutical formulations; LATAM and Africa via Caplin Point; US via CSL/CSU.

Dividend details

• Record Date: 18-09-2026 for AGM and final dividend.
• AGM date planned for 25 September 2026.
• Final dividend for FY 2025-26 will be paid if declared.
• Face value: Rs 2 per equity share.
• Dividend type: final, subject to AGM approval.

Financial results

• Unaudited standalone and consolidated results for quarter ended 30-06-2026 approved with Limited Review Report.

Dividend proposal

• Final dividend recommended for FY2025-26: Rs 4 per equity share (200%).

Record date

• Record date approved for dividend eligibility.

Management appointments

• Dr. Sridhar Ganesan re-appointed MD for two years from 25 Aug 2026.
• D. Muralidharan appointed Whole-Time Director for two years from 12 Aug 2026; continues as CFO.

AGM and other dates

• 35th AGM to be held on 25 Sep 2026 via video conferencing.

Regulatory disclosures

• Annexure 5 outlines change in Directors under SEBI Listing Regulations.

Investors materials

• Press release, Annexures 1–4 and investor presentation approved/issued.

Meeting Details

• Post-results Q1 FY27 earnings conference call scheduled for Aug 12, 2026 at 4:30 PM IST.
• Organiser: Caplin Point Laboratories Limited; virtual conference call invitation issued.
• Company participants: Chairman, two Vice Chairmen, Managing Director, Chief Financial Officer.
• Purpose: discuss Q1 FY27 financial performance for quarter ended June 30, 2026.
• Pre-registration via DiamondPass required to join.

Meeting Details

• Date: August 12, 2026; time and venue not disclosed.

Key Agenda Items

• Quarterly unaudited standalone and consolidated results for quarter ended June 30, 2026.
• Recommendation of Final Dividend for FY 2025-26 for shareholder approval.
• Convening the 35th Annual General Meeting of the Company.
• Fixation of record date for eligibility for Final Dividend.

Other Notes

• Trading window closed July 01, 2026 to August 14, 2026 for insiders.